Transparency Reporting: Status

Slides:



Advertisements
Similar presentations
© 2013 Sri U-Thong Limited. All rights reserved. This presentation has been prepared by Sri U-Thong Limited and its holding company (collectively, “Sri.
Advertisements

CA ERwin r8 installing the application things you should know before installing your CA ERwin r8 Data modeling application.
Primo Workbook #2 Supplemental Screenshots. 2 Copyright Statement and Disclaimer All of the information and material, including text, images, logos and.
Innovations in Structured Products October 25, 2010 An Innovator’s Dilemma?
Works Cardholder Tutorial Initial Login, Transaction Review, & Reports.
An Equity Perspective Paul Malan Global Markets 21 January 2004.
Adding Genes This presentation gives a quick overview on how to add Genes to Osprey.
PRODUCTIVITY – THE PICTURE FOR THE UK & THE WEST MIDLANDS SUSTAINING COMPETITIVENESS CONFERENCE – THE BELFRY RHYS HERBERT SENIOR ECONOMIST 6 JULY 2012.
MESSAGING IN THE MEDIA TOP 10 DRUGS BASED ON CREDIBILITY INDEX IN THE LITERATURE JOHN KNAPP, DIRECTOR OF ANALYTICS MAY 2009 Your use of these materials.
End User License Agreement Permission to use and redistribute this Document is granted, provided that (1) the below copyright notice appears in all copies.
Therapeutic area breakdown of lead projects in development for first launch in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM ©
Paragraph IV Patent Challenges – As of July 1, 2008 JULY 2008 David Harding, API Intelligence, Thomson Reuters Source: FDA, NEWPORT HORIZON PREMIUM TM.
Proportion of biotech-derived active substances in development for first launch 31st December APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
Oracle Fusion Applications 11gR1 ( ) Functional Overview (L2) Manage Inbound Logistics (L3) Manage Receipts.
Oracle Fusion Applications 11gR1 ( ) Functional Overview (L2) Manage Inbound Logistics (L3) Put Away Loads.
Oracle Fusion Applications 11gR1 ( ) Functional Overview (L2) Manage Inbound Logistics (L3) Manage Supplier Returns.
1 XIII: Electronic Resources Managing Trials and Evaluations.
Proportion of total R&D expenditure by therapeutic area in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS Your.
Oracle Fusion Applications 11gR1 ( ) Functional Overview (L2) Manage Inbound Logistics (L3) Manage and Disposition Inventory Returns.
Global R&D expenditure, development times, global pharmaceutical sales and new molecular entity output MARCH 2008 SOURCE: CMR INTERNATIONAL.
Oracle Fusion Applications 11gR1 ( ) Functional Overview (L2) Manage Inbound Logistics (L3) Inspect Material.
1 SFX TotalCare: User Interface Configuration - A-Z List.
2005/2006 Expenditure on biotech derived entities had remained constant APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS.
1 Pick and Scan Voyager 9. 2 Copyright Statement All of the information and material inclusive of text, images, logos, product names is either the property.
-1- Oracle E-Business Suite R12.1 Accounts Receivables Essentials Partner Boot Camp Training Courseware.
Number of pharmaceutical patent applications and granted patents for 5 major patent issuing authorities JUNE 2008 SOURCE: DERWENT WORLD PATENTS.
Regulatory approval times between submission and marketing authorization approval APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.
Availability of High-Quality API for India, China and Rest of World MARCH 2008 David Harding, API Intelligence, Thomson Reuters Source: NEWPORT HORIZON.
End User License Agreement Permission to use and redistribute this Document is granted, provided that (1) the below copyright notice appears in all copies.
Allocation of R&D expenditure in 2005 between chemical entity and biological or biotech active substances APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
The economic outlook. 2 Greece Russia 3 The deflation-ghost.
Permission to reprint or distribute any content from this presentation requires the prior written approval of Standard & Poor’s. Copyright © 2011 Standard.
The secure site rendering issue (all navigation crushed together as a list at the top of the page) is a compatibility issue with Internet Explorer only.
ERES 2016: “Solvency II – Optimising regulatory capital required to be held against real estate assets. A Case Study” Charles Ostroumoff 10 th June, 2016.
1 Designing and using normalization rules Yoel Kortick Senior Librarian, Ex Libris.
Copyright © 2012, Oracle and/or its affiliates. All rights reserved. Oracle Proprietary and Confidential. 1.
STOCK OPTIONS MONTHLY REPORT
HRMS At India Infoline 2008.
Achieving innovation to meet new market challenges: Global Commodity Financing GTR MENA Oscar Wehtje, Head of Product Development February 2017.
technology in retirement savings
<Insert Picture Here>
BIOLOGY / CHEMISTRY CITATIONS GROWTH
Selecting the right provider
Under-rated assets in an over-priced world
Navigating the Portal 18 December 2017 Version 1.0.
This presentation document has been prepared by Vault Intelligence Limited (“Vault") and is intended for off line demonstration, presentation and educational.
Automation in an XML Authoring Environment
Messaging in the Media TOP 10 AUDIENCES BY THERAPY AREA
Transparency: Exceptions
This presentation document has been prepared by Vault Intelligence Limited (“Vault") and is intended for off line demonstration, presentation and educational.
Transaction Reporting: Sources
, R&D expenditure showed 6% growth annually
Comparative Reporting & Analysis (CR&A)
To the ETS – PNG Continuation: Online Training Course
Proportion of total R&D expenditure on alliances or joint ventures by stage of R&D in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.
This presentation document has been prepared by Vault Intelligence Limited (“Vault") and is intended for off line demonstration, presentation and educational.
Transaction Reporting: Exception Handling
This presentation document has been prepared by Vault Intelligence Limited (“Vault") and is intended for off line demonstration, presentation and educational.
This presentation document has been prepared by Vault Intelligence Limited (“Vault") and is intended for off line demonstration, presentation and educational.
<Insert Picture Here>
Cycle times decreased in larger but not smaller, companies
This presentation document has been prepared by Vault Intelligence Limited (“Vault") and is intended for off line demonstration, presentation and educational.
This presentation document has been prepared by Vault Intelligence Limited (“Vault") and is intended for off line demonstration, presentation and educational.
Proportion of total R&D expenditure by function in 2005
FOCUS SFTR Version 01 – Updated in January 2019.
This presentation document has been prepared by Vault Intelligence Limited (“Vault") and is intended for off line demonstration, presentation and educational.
© 2013 Sri U-Thong Limited. All rights reserved
This presentation document has been prepared by Vault Intelligence Limited (“Vault") and is intended for off line demonstration, presentation and educational.
This presentation document has been prepared by Vault Intelligence Limited (“Vault") and is intended for off line demonstration, presentation and educational.
Adding signatures to outgoing in Webmail and Microsoft Outlook
Presentation transcript:

Transparency Reporting: Status 18 December 2017 Version 1.0

Transparency Reporting: Status Table This guide covers the following aspects of the NEX Regulatory Reporting Portal… Transparency Reporting: Status Table Transparency Reporting: Trade Level Drilldown 31 December 2018 Confidential

Transparency Reporting: Status Table Other filters are also available for the status data and can be applied independently or in combination. Note that the full value is required to search on the free text fields (Message ID, Client Reference etc.) Once all required filters have been entered or selected, please click ‘Apply’ to see the updated results. Filters can be removed at any stage by selecting ‘Reset’. The Status page, and in particular the Publication Status table, is central to Transparency Reporting, providing a running view of records as they are successfully processed by the APA. The table automatically refreshes every minute though a page refresh can also be used to update the Status table. The Publication Status table can be filtered on the status of records as required by using the relevant tick boxes and then clicking ‘Apply’. Hovering over either the Message ID or Client Reference fields gives the user the option to copy the value to the clipboard for use elsewhere. Hovering over the information tooltips provides details as to what each field in the table represents. 31 December 2018 Confidential

Transparency Reporting: Trade Level Drilldown The Trade screen is comprised of two sections, the first of which is the header. This includes key information from the APA such as the status and timestamps. The second section contains the technical details as received from the client or enriched by the APA. From the Publication Status table, it is possible to drilldown into the details of any Trade record by clicking anywhere on the relevant line (highlighted in turquoise as a user hovers over). Please note that at this stage, it isn’t yet possible to drill down into individual Quotes though this functionality will be added in the near future. 31 December 2018 Confidential

Thank you Should you have any questions, please contact abide Thank you Should you have any questions, please contact abide.operations@abide-financial.com All information contained herein (“Information”) is for informational purposes only, is confidential and is the intellectual property of NEX Group plc and/or one of its group companies (“NEX”). The Information is directed to Eligible Counterparties and Professional Customers only and is not intended for Retail Clients (as each term is defined by the rules of the Financial Conduct Authority ("FCA")) or equivalent in a relevant jurisdiction. This Information is not, and should not be construed as, an offer or solicitation to sell or buy any product, investment, security or any other financial instrument or to participate in any particular trading strategy. The Information is not to be relied upon and is not warranted, either expressly or by implication, as to completeness, timeliness, accuracy, merchantability or fitness for any particular purpose. All representations and warranties are expressly disclaimed. Access to the Information by anyone other than the intended recipient is unauthorised and any disclosure, copying or redistribution is prohibited without NEX’s prior written approval. If you receive this information in error, please immediately delete all copies of it and notify the sender. In no circumstances will NEX be liable for any indirect or direct loss, or consequential loss or damages including without limitation, loss of business or profits arising from the use of, any inability to use, or any inaccuracy in the Information. NEX and the NEX logo are trademarks of the NEX group. Certain NEX group companies are regulated by regulatory authorities. For further regulatory information, please see www.nex.com. ©NEX Group plc 2017